Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.
This study aims at developing and characterizing the puerarin dry powder inhaler (DPI) formulations for pulmonary delivery. The inhalable particles size (<2 μm) was accomplished by micronization and its morphology was examined by scanning electron microscopy (SEM). The puerarin-excipient interact...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0249683&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850042380225347584 |
|---|---|
| author | Md Abdur Rashid Saiqa Muneer Tony Wang Yahya Alhamhoom Llew Rintoul Emad L Izake Nazrul Islam |
| author_facet | Md Abdur Rashid Saiqa Muneer Tony Wang Yahya Alhamhoom Llew Rintoul Emad L Izake Nazrul Islam |
| author_sort | Md Abdur Rashid |
| collection | DOAJ |
| description | This study aims at developing and characterizing the puerarin dry powder inhaler (DPI) formulations for pulmonary delivery. The inhalable particles size (<2 μm) was accomplished by micronization and its morphology was examined by scanning electron microscopy (SEM). The puerarin-excipient interaction in powder mixtures was analyzed by using Fourier transform infrared spectroscopy (FTIR), Raman confocal microscopy, X-Ray powder Diffraction (XRD), and differential scanning calorimetry (DSC) methods. Using a Twin stage impinger (TSI), the in-vitro aerosolization of the powder formulations was carried out at a flow rate of 60 L/min and the drug was quantified by employing a validated HPLC method. No significant interactions between the drug and the excipients were observed in the powder formulations. The fine particle fraction (FPF) of the drug alone was 4.2% which has increased five to six-fold for the formulations with aerosolization enhancers. Formulation containing lactose as large carriers produced 32.7% FPF, which further increased with the addition of dispersibility enhancers, leucine and magnesium stearate (40.8% and 41.2%, respectively). The Raman and FTIR techniques are very useful tool for understanding structural integrity and stability of the puerarin in the powder formulations. The puerarin was found to be compatible with the excipients used and the developed DPI formulation may be considered as an efficient formulation for pulmonary delivery for the management of various diseases at a very low dose. |
| format | Article |
| id | doaj-art-802a930be9eb4ced9872733395254e63 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-802a930be9eb4ced9872733395254e632025-08-20T02:55:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01164e024968310.1371/journal.pone.0249683Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.Md Abdur RashidSaiqa MuneerTony WangYahya AlhamhoomLlew RintoulEmad L IzakeNazrul IslamThis study aims at developing and characterizing the puerarin dry powder inhaler (DPI) formulations for pulmonary delivery. The inhalable particles size (<2 μm) was accomplished by micronization and its morphology was examined by scanning electron microscopy (SEM). The puerarin-excipient interaction in powder mixtures was analyzed by using Fourier transform infrared spectroscopy (FTIR), Raman confocal microscopy, X-Ray powder Diffraction (XRD), and differential scanning calorimetry (DSC) methods. Using a Twin stage impinger (TSI), the in-vitro aerosolization of the powder formulations was carried out at a flow rate of 60 L/min and the drug was quantified by employing a validated HPLC method. No significant interactions between the drug and the excipients were observed in the powder formulations. The fine particle fraction (FPF) of the drug alone was 4.2% which has increased five to six-fold for the formulations with aerosolization enhancers. Formulation containing lactose as large carriers produced 32.7% FPF, which further increased with the addition of dispersibility enhancers, leucine and magnesium stearate (40.8% and 41.2%, respectively). The Raman and FTIR techniques are very useful tool for understanding structural integrity and stability of the puerarin in the powder formulations. The puerarin was found to be compatible with the excipients used and the developed DPI formulation may be considered as an efficient formulation for pulmonary delivery for the management of various diseases at a very low dose.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0249683&type=printable |
| spellingShingle | Md Abdur Rashid Saiqa Muneer Tony Wang Yahya Alhamhoom Llew Rintoul Emad L Izake Nazrul Islam Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization. PLoS ONE |
| title | Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization. |
| title_full | Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization. |
| title_fullStr | Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization. |
| title_full_unstemmed | Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization. |
| title_short | Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization. |
| title_sort | puerarin dry powder inhaler formulations for pulmonary delivery development and characterization |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0249683&type=printable |
| work_keys_str_mv | AT mdabdurrashid puerarindrypowderinhalerformulationsforpulmonarydeliverydevelopmentandcharacterization AT saiqamuneer puerarindrypowderinhalerformulationsforpulmonarydeliverydevelopmentandcharacterization AT tonywang puerarindrypowderinhalerformulationsforpulmonarydeliverydevelopmentandcharacterization AT yahyaalhamhoom puerarindrypowderinhalerformulationsforpulmonarydeliverydevelopmentandcharacterization AT llewrintoul puerarindrypowderinhalerformulationsforpulmonarydeliverydevelopmentandcharacterization AT emadlizake puerarindrypowderinhalerformulationsforpulmonarydeliverydevelopmentandcharacterization AT nazrulislam puerarindrypowderinhalerformulationsforpulmonarydeliverydevelopmentandcharacterization |